We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here is What to Know Beyond Why Teladoc Health, Inc. (TDOC) is a Trending Stock
Read MoreHide Full Article
Teladoc (TDOC - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this telehealth services provider have returned +30.6%, compared to the Zacks S&P 500 composite's +5.6% change. During this period, the Zacks Medical Services industry, which Teladoc falls in, has gained 7.6%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Teladoc is expected to post a loss of $0.27 per share, indicating a change of -285.7% from the year-ago quarter. The Zacks Consensus Estimate has changed +3.6% over the last 30 days.
The consensus earnings estimate of -$61.29 for the current fiscal year indicates a year-over-year change of -4,508.3%. This estimate has changed +0.6% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of -$1.39 indicates a change of +97.7% from what Teladoc is expected to report a year ago. Over the past month, the estimate has changed -0.7%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Teladoc is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Teladoc, the consensus sales estimate of $633.56 million for the current quarter points to a year-over-year change of +14.3%. The $2.4 billion and $2.71 billion estimates for the current and next fiscal years indicate changes of +18.2% and +12.7%, respectively.
Last Reported Results and Surprise History
Teladoc reported revenues of $611.4 million in the last reported quarter, representing a year-over-year change of +17.2%. EPS of -$0.45 for the same period compares with -$0.53 a year ago.
Compared to the Zacks Consensus Estimate of $609.45 million, the reported revenues represent a surprise of +0.32%. The EPS surprise was +23.73%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Teladoc is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Teladoc. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here is What to Know Beyond Why Teladoc Health, Inc. (TDOC) is a Trending Stock
Teladoc (TDOC - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this telehealth services provider have returned +30.6%, compared to the Zacks S&P 500 composite's +5.6% change. During this period, the Zacks Medical Services industry, which Teladoc falls in, has gained 7.6%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Teladoc is expected to post a loss of $0.27 per share, indicating a change of -285.7% from the year-ago quarter. The Zacks Consensus Estimate has changed +3.6% over the last 30 days.
The consensus earnings estimate of -$61.29 for the current fiscal year indicates a year-over-year change of -4,508.3%. This estimate has changed +0.6% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of -$1.39 indicates a change of +97.7% from what Teladoc is expected to report a year ago. Over the past month, the estimate has changed -0.7%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Teladoc is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Teladoc, the consensus sales estimate of $633.56 million for the current quarter points to a year-over-year change of +14.3%. The $2.4 billion and $2.71 billion estimates for the current and next fiscal years indicate changes of +18.2% and +12.7%, respectively.
Last Reported Results and Surprise History
Teladoc reported revenues of $611.4 million in the last reported quarter, representing a year-over-year change of +17.2%. EPS of -$0.45 for the same period compares with -$0.53 a year ago.
Compared to the Zacks Consensus Estimate of $609.45 million, the reported revenues represent a surprise of +0.32%. The EPS surprise was +23.73%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Teladoc is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Teladoc. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.